54,832 Shares in Arvinas, Inc. $ARVN Purchased by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC acquired a new stake in Arvinas, Inc. (NASDAQ:ARVN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 54,832 shares of the company’s stock, valued at approximately $404,000. Campbell & CO Investment Adviser LLC owned approximately 0.08% of Arvinas at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ARVN. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Arvinas in the second quarter valued at approximately $634,000. Los Angeles Capital Management LLC lifted its holdings in Arvinas by 41.8% in the second quarter. Los Angeles Capital Management LLC now owns 39,801 shares of the company’s stock valued at $293,000 after acquiring an additional 11,740 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Arvinas during the 2nd quarter worth $1,073,000. AlphaQuest LLC grew its stake in shares of Arvinas by 18.7% during the 2nd quarter. AlphaQuest LLC now owns 19,573 shares of the company’s stock worth $144,000 after purchasing an additional 3,086 shares during the period. Finally, FNY Investment Advisers LLC purchased a new position in shares of Arvinas in the 2nd quarter valued at about $276,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Briggs Morrison bought 30,000 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were purchased at an average price of $7.57 per share, for a total transaction of $227,100.00. Following the completion of the transaction, the director owned 76,021 shares in the company, valued at $575,478.97. The trade was a 65.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.73% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on ARVN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Arvinas in a research note on Wednesday, October 8th. Guggenheim reduced their price target on shares of Arvinas from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Barclays boosted their price target on Arvinas from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Stephens raised their price objective on Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. Finally, HC Wainwright decreased their target price on Arvinas from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Arvinas currently has a consensus rating of “Hold” and an average price target of $16.39.

Arvinas Stock Performance

Arvinas stock opened at $10.57 on Monday. Arvinas, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $27.00. The company has a market capitalization of $678.81 million, a price-to-earnings ratio of -13.05 and a beta of 2.38. The stock has a fifty day moving average of $9.12 and a two-hundred day moving average of $7.95.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.27. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The business had revenue of $41.90 million for the quarter, compared to analyst estimates of $29.36 million. During the same quarter last year, the company earned ($0.68) earnings per share. The business’s revenue for the quarter was down 59.1% compared to the same quarter last year. On average, analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Arvinas declared that its Board of Directors has authorized a stock buyback plan on Wednesday, September 17th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the company to repurchase up to 17.9% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.